Advisory Committee; Anesthetic and Analgesic Drug Products Advisory Committee; Renewal, 63434-63435 [2024-17248]
Download as PDF
<![CDATA[
63434
Federal Register / Vol. 89, No. 150 / Monday, August 5, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity; ‘‘State SNAP Agency NDNH
Matching Program Performance
Report’’ (Office of Management Budget
#0970–0464)
Office of Child Support
Services, Administration for Children
and Families, U.S. Department of Health
and Human Services.
ACTION: Request for public comments.
AGENCY:
The Office of Child Support
Services (OCSS) is requesting the
federal Office of Management and
Budget (OMB)approve the ‘‘State SNAP
Agency NDNH Matching Program
Performance Report,’’ with minor
revisions, for an additional three years.
State agencies administering their
Supplemental Nutrition Assistance
SUMMARY:
Program (SNAP) provide the annual
performance report to OCSS in
accordance with the computer matching
agreement between state SNAP agencies
and OCSS. The current OMB approval
expires on February 28, 2025.
DATES: Comments due within 60 days of
publication. In compliance with the
requirements of the Paperwork
Reduction Act of 1995, the
Administration for Children and
Families is soliciting public comment
on the specific aspects of the
information collection described above.
ADDRESSES: To submit comments and
obtain copies of the proposed collection
of information, email infocollection@
acf.hhs.gov. Identify all requests by the
title of the information collection.
SUPPLEMENTARY INFORMATION:
Description: State agencies
administering SNAP are mandated to
participate in a computer matching
program with OCSS. The matching
program compares SNAP applicant and
recipient information with employment
and wage information maintained in the
National Directory of New Hires
(NDNH). The outcomes of the compared
information help state SNAP agencies
verify an individual’s identity and
determine a benefit eligibility. To
receive NDNH information, state
agencies enter into a computer matching
agreement and adhere to its terms and
conditions, including providing OCSS
with annual performance outcomes
attributable to the use of NDNH
information. To fulfill OMB
requirements, OCSS periodically reports
performance measurements
demonstrating how the use of
information in the NDNH supports the
OCSS strategic mission, goals, and
objectives. These periodic reports
include information derived from state
SNAP agency annual NDNH
performance reports. OCSS provides
states with required performance report
templates and instructions, which
underwent minor language edits.
Respondents: State SNAP Agencies.
ANNUAL BURDEN ESTIMATES
Instrument
Total
number of respondents
Annual
number of
responses per
respondent
Average
burden hours
per response
Total annual
burden hours
SNAP Agency Performance Reporting Tool and Instructions .........................
53
1
0.83
43.99
Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. OCSS will consider
comments and suggestions submitted
within 60 days of this publication.
Authority: 42 U.S.C. 653(j)(10); 5
U.S.C. 552a; and Public Law 111–352.
Mary C. Jones, ACF/OPRE Certifying Officer.
lotter on DSK11XQN23PROD with NOTICES1
[FR Doc. 2024–17148 Filed 8–2–24; 8:45 am]
BILLING CODE 4184–41–P
VerDate Sep<11>2014
18:38 Aug 02, 2024
Jkt 262001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2022–N–0621]
Advisory Committee; Anesthetic and
Analgesic Drug Products Advisory
Committee; Renewal
AGENCY:
Food and Drug Administration,
HHS.
Notice; renewal of Federal
advisory committee.
ACTION:
The Food and Drug
Administration (FDA or the Agency) is
announcing the renewal of the
Anesthetic and Analgesic Drug Products
Advisory Committee by the
Commissioner of Food and Drugs (the
Commissioner). The Commissioner has
determined that it is in the public
interest to renew the Anesthetic and
Analgesic Drug Products Advisory
Committee for an additional 2 years
beyond the charter expiration date. The
new charter will be in effect until the
May 1, 2026, expiration date.
DATES: Authority for the Anesthetic and
Analgesic Drug Products Advisory
Committee will expire on May 1, 2026,
SUMMARY:
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
unless the Commissioner formally
determines that renewal is in the public
interest.
FOR FURTHER INFORMATION CONTACT:
Joyce Frimpong, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–7973, email: AADPAC@
fda.hhs.gov.
Pursuant
to 41 CFR 102–3.65 and approval by the
Department of Health and Human
Services and by the General Services
Administration, FDA is announcing the
renewal of the Anesthetic and Analgesic
Drug Products Advisory Committee (the
Committee). The Committee is a
discretionary Federal advisory
committee established to provide advice
to the Commissioner. The Committee
advises the Commissioner or designee
in discharging responsibilities as they
relate to helping to ensure safe and
effective drugs for human use and, as
required, any other product for which
FDA has regulatory responsibility.
The Committee reviews and evaluates
available data concerning the safety and
effectiveness of marketed and
SUPPLEMENTARY INFORMATION:
E:\FR\FM\05AUN1.SGM
05AUN1
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 150 / Monday, August 5, 2024 / Notices
investigational human drug products
including analgesics; e.g., abusedeterrent opioids, novel analgesics, and
issues related to opioid abuse, and those
for use in anesthesiology and makes
appropriate recommendations to the
Commissioner of Food and Drugs.
Pursuant to its charter, the Committee
shall consist of a core of 11 voting
members including the Chair. Members
and the Chair are selected by the
Commissioner or designee from among
authorities knowledgeable in the fields
of anesthesiology, analgesics (such as:
abuse deterrent opioids, novel
analgesics, and issues related to opioid
abuse) epidemiology or statistics, and
related specialties. Members will be
invited to serve for overlapping terms of
up to 4 years. Non-Federal members of
this committee will serve as Special
Government Employees or
representatives. Federal members will
serve as Regular Government Employees
or Ex-Officios. The core of voting
members may include one technically
qualified member, selected by the
Commissioner or designee, who is
identified with consumer interests and
is recommended by either a consortium
of consumer-oriented organizations or
other interested persons. In addition to
the voting members, the Committee may
include one non-voting representative
member who is identified with industry
interests. There may also be an alternate
industry representative.
The Commissioner or designee shall
have the authority to select members of
other scientific and technical FDA
advisory committees (normally not to
exceed 10 members) to serve
temporarily as voting members and to
designate consultants to serve
temporarily as voting members when:
(1) expertise is required that is not
available among current voting standing
members of the Committee (when
additional voting members are added to
the Committee to provide needed
expertise, a quorum will be based on the
combined total of regular and added
members) or (2) to comprise a quorum
when, because of unforeseen
circumstances, a quorum is or will be
lacking. Because of the size of the
Committee and the variety in the types
of issues that it will consider, FDA may,
in connection with a particular
committee meeting, specify a quorum
that is less than a majority of the current
voting members. The Agency’s
regulations (21 CFR 14.22(d)) authorize
a committee charter to specify quorum
requirements.
If functioning as a medical device
panel, an additional non-voting
representative member of consumer
interests and an additional non-voting
VerDate Sep<11>2014
18:38 Aug 02, 2024
Jkt 262001
representative member of industry
interests will be included in addition to
the voting members.
Further information regarding the
most recent charter and other
information can be found at https://
www.fda.gov/advisory-committees/
human-drug-advisory-committees/
anesthetic-and-analgesic-drug-productsadvisory-committee or by contacting the
Designated Federal Officer (see FOR
FURTHER INFORMATION CONTACT). In light
of the fact that no change has been made
to the committee name or description of
duties, no amendment will be made to
21 CFR 14.100.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. 1001 et seq.). For general
information related to FDA advisory
committees, please visit us at https://
www.fda.gov/AdvisoryCommittees/
default.htm.
Dated: July 31, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024–17248 Filed 8–2–24; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2022–N–0618]
Advisory Committee; Drug Safety and
Risk Management Advisory
Committee; Renewal
AGENCY:
Food and Drug Administration,
HHS.
Notice; renewal of Federal
advisory committee.
ACTION:
The Food and Drug
Administration (FDA or the Agency) is
announcing the renewal of the Drug
Safety and Risk Management Advisory
Committee by the Commissioner of
Food and Drugs (the Commissioner).
The Commissioner has determined that
it is in the public interest to renew the
Drug Safety and Risk Management
Advisory Committee for an additional 2
years beyond the charter expiration
date. The new charter will be in effect
until the May 31, 2026, expiration date.
DATES: Authority for the Drug Safety
and Risk Management Advisory
Committee will expire on May 31, 2026,
unless the Commissioner formally
determines that renewal is in the public
interest.
FOR FURTHER INFORMATION CONTACT:
Moon Choi, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
SUMMARY:
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
63435
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, (240) 743–8319,
DSaRM@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to 41 CFR 102–3.65 and approval by the
Department of Health and Human
Services (HHS) and by the General
Services Administration, FDA is
announcing the renewal of the Drug
Safety and Risk Management Advisory
Committee (the Committee). The
Committee is a discretionary Federal
advisory committee established to
provide advice to the Commissioner.
The Committee advises the
Commissioner or designee in
discharging responsibilities as they
relate to helping to ensure safe and
effective drugs for human use and, as
required, any other product for which
FDA has regulatory responsibility.
The Committee reviews and evaluates
information on risk management, risk
communication, and quantitative
evaluation of spontaneous reports for
drugs for human use and for any other
product for which FDA has regulatory
responsibility. The Committee also
advises the Commissioner regarding the
scientific and medical evaluation of all
information gathered by HHS and the
Department of Justice with regard to
safety, efficacy, and abuse potential of
drugs or other substances, and
recommends actions to be taken by HHS
with regard to the marketing,
investigation, and control of such drugs
or other substances.
Pursuant to its Charter, the Committee
shall consist of a core of 11 voting
members including the Chair. Members
and the Chair are selected by the
Commissioner or designee from among
authorities knowledgeable in the fields
of risk communication, risk
management, drug safety, medical,
behavioral, and biological sciences as
they apply to risk management, and
drug abuse. Members will be invited to
serve for overlapping terms of up to 4
years. Non-Federal members of this
committee will serve as Special
Government Employees or
representatives. Federal members will
serve as Regular Government Employees
or Ex-Officios. The core of voting
members may include one technically
qualified member, selected by the
Commissioner or designee, who is
identified with consumer interests and
is recommended by either a consortium
of consumer-oriented organizations or
other interested persons. In addition to
the voting members, the Committee may
include one non-voting representative
member who is identified with industry
interests. There may also be an alternate
industry representative.
E:\FR\FM\05AUN1.SGM
05AUN1
]]>Agencies
[Federal Register Volume 89, Number 150 (Monday, August 5, 2024)]
[Notices]
[Pages 63434-63435]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-17248]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-0621]
Advisory Committee; Anesthetic and Analgesic Drug Products
Advisory Committee; Renewal
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; renewal of Federal advisory committee.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) is
announcing the renewal of the Anesthetic and Analgesic Drug Products
Advisory Committee by the Commissioner of Food and Drugs (the
Commissioner). The Commissioner has determined that it is in the public
interest to renew the Anesthetic and Analgesic Drug Products Advisory
Committee for an additional 2 years beyond the charter expiration date.
The new charter will be in effect until the May 1, 2026, expiration
date.
DATES: Authority for the Anesthetic and Analgesic Drug Products
Advisory Committee will expire on May 1, 2026, unless the Commissioner
formally determines that renewal is in the public interest.
FOR FURTHER INFORMATION CONTACT: Joyce Frimpong, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-7973, email: [email protected].
SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by
the Department of Health and Human Services and by the General Services
Administration, FDA is announcing the renewal of the Anesthetic and
Analgesic Drug Products Advisory Committee (the Committee). The
Committee is a discretionary Federal advisory committee established to
provide advice to the Commissioner. The Committee advises the
Commissioner or designee in discharging responsibilities as they relate
to helping to ensure safe and effective drugs for human use and, as
required, any other product for which FDA has regulatory
responsibility.
The Committee reviews and evaluates available data concerning the
safety and effectiveness of marketed and
[[Page 63435]]
investigational human drug products including analgesics; e.g., abuse-
deterrent opioids, novel analgesics, and issues related to opioid
abuse, and those for use in anesthesiology and makes appropriate
recommendations to the Commissioner of Food and Drugs.
Pursuant to its charter, the Committee shall consist of a core of
11 voting members including the Chair. Members and the Chair are
selected by the Commissioner or designee from among authorities
knowledgeable in the fields of anesthesiology, analgesics (such as:
abuse deterrent opioids, novel analgesics, and issues related to opioid
abuse) epidemiology or statistics, and related specialties. Members
will be invited to serve for overlapping terms of up to 4 years. Non-
Federal members of this committee will serve as Special Government
Employees or representatives. Federal members will serve as Regular
Government Employees or Ex-Officios. The core of voting members may
include one technically qualified member, selected by the Commissioner
or designee, who is identified with consumer interests and is
recommended by either a consortium of consumer-oriented organizations
or other interested persons. In addition to the voting members, the
Committee may include one non-voting representative member who is
identified with industry interests. There may also be an alternate
industry representative.
The Commissioner or designee shall have the authority to select
members of other scientific and technical FDA advisory committees
(normally not to exceed 10 members) to serve temporarily as voting
members and to designate consultants to serve temporarily as voting
members when: (1) expertise is required that is not available among
current voting standing members of the Committee (when additional
voting members are added to the Committee to provide needed expertise,
a quorum will be based on the combined total of regular and added
members) or (2) to comprise a quorum when, because of unforeseen
circumstances, a quorum is or will be lacking. Because of the size of
the Committee and the variety in the types of issues that it will
consider, FDA may, in connection with a particular committee meeting,
specify a quorum that is less than a majority of the current voting
members. The Agency's regulations (21 CFR 14.22(d)) authorize a
committee charter to specify quorum requirements.
If functioning as a medical device panel, an additional non-voting
representative member of consumer interests and an additional non-
voting representative member of industry interests will be included in
addition to the voting members.
Further information regarding the most recent charter and other
information can be found at https://www.fda.gov/advisory-committees/human-drug-advisory-committees/anesthetic-and-analgesic-drug-products-advisory-committee or by contacting the Designated Federal Officer (see
FOR FURTHER INFORMATION CONTACT). In light of the fact that no change
has been made to the committee name or description of duties, no
amendment will be made to 21 CFR 14.100.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. 1001 et seq.). For general information related to FDA advisory
committees, please visit us at https://www.fda.gov/AdvisoryCommittees/default.htm.
Dated: July 31, 2024.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2024-17248 Filed 8-2-24; 8:45 am]
BILLING CODE 4164-01-P
